Rosemarie Aurigemma
Overview
Explore the profile of Rosemarie Aurigemma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
307
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arisa O, Beatson E, Reno A, Chau C, Aurigemma R, Steeg P, et al.
Lancet Oncol
. 2024 Dec;
25(12):e685-e693.
PMID: 39637905
The translation of basic drug discoveries from laboratories to clinical use presents substantial challenges. Factors such as insufficient funding, misdirected project focus, and inability to understand a drug's limitations or...
2.
Fogli L, Aurigemma R, Sommers C, Singh A, Bourcier K, Ernstoff M
J Immunother Cancer
. 2021 Jul;
9(7).
PMID: 34266886
Cell-based immunotherapies have had remarkable success in the clinic, specifically in the treatment of hematologic malignancies. However, these strategies have had limited efficacy in patients with solid tumors. To better...
3.
Outterson K, Rex J, Jinks T, Jackson P, Hallinan J, Karp S, et al.
Nat Rev Drug Discov
. 2016 Jul;
15(9):589-590.
PMID: 27469032
A global response to the chronic shortfall in antibiotic innovation is urgently needed to combat antimicrobial resistance. Here, we introduce CARB-X, a new global public-private partnership that will invest more...
4.
Kim K, Dmitriev I, Saddekni S, Kashentseva E, Harris R, Aurigemma R, et al.
Gynecol Oncol
. 2013 Jun;
130(3):518-24.
PMID: 23756180
Objective: The conditionally replicative adenovirus Ad5/3-Δ24 has a type-3 knob incorporated into the type-5 fiber that facilitates enhanced ovarian cancer infectivity. Preclinical studies have shown that Ad5/3-Δ24 achieves significant oncolysis...
5.
Lipsitz R, Garges S, Aurigemma R, Baccam P, Blaney D, Cheng A, et al.
Emerg Infect Dis
. 2012 Nov;
18(12):e2.
PMID: 23171644
The US Public Health Emergency Medical Countermeasures Enterprise convened subject matter experts at the 2010 HHS Burkholderia Workshop to develop consensus recommendations for postexposure prophylaxis against and treatment for Burkholderia...
6.
Kim K, Dmitriev I, OMalley J, Wang M, Saddekni S, You Z, et al.
Clin Cancer Res
. 2012 Apr;
18(12):3440-51.
PMID: 22510347
Purpose: Ad5.SSTR/TK.RGD is an infectivity-enhanced adenovirus expressing a therapeutic thymidine kinase suicide gene and a somatostatin receptor (SSTR) that allows for noninvasive gene transfer imaging. The purpose of this study...
7.
Kim K, Ryan M, Estep J, Miniard B, Rudge T, Peggins J, et al.
Hum Gene Ther
. 2010 Dec;
22(7):821-8.
PMID: 21171861
Conditionally replicative adenoviral (CRAd) virotherapy represents a promising therapeutic approach for cancer. We have demonstrated that a serotype chimeric adenoviral 5/3 fiber-knob modification achieves enhanced ovarian cancer infectivity, conditional replication,...
8.
Kimball K, Preuss M, Barnes M, Wang M, Siegal G, Wan W, et al.
Clin Cancer Res
. 2010 Oct;
16(21):5277-87.
PMID: 20978148
Purpose: To determine the maximum tolerated dose (MTD), toxicity spectrum, clinical activity, and biological effects of the tropism-modified, infectivity-enhanced conditionally replicative adenovirus (CRAd), Ad5-Δ24-Arg-Gly-Asp (RGD), in patients with malignant gynecologic...
9.
Belousova N, Harris R, Zinn K, Rhodes-Selser M, Kotov A, Kotova O, et al.
Mol Pharmacol
. 2006 Aug;
70(5):1488-93.
PMID: 16896072
Delivery of multiple exogenous genes into target cells is important for a broad range of gene therapy applications, including combined therapeutic gene expression and noninvasive imaging. Previous studies ( Mol...